The IL-23 inhibitor from AbbVie indicated for the treatment of
moderate to severe plaque psoriasis (Ps) in adults who are candidates for systemic
therapy or phototherapy and for adults with active psoriatic arthritis (PsA).¹

SKYRIZI is available as
a single 150 mg injection¹

SKYRIZI is the only 4-dose-a-year biologic for Ps and for PsA
that offers a single-dose pen¹

SKYRIZI is also available in a single-dose 150 mg/mL prefilled syringe.¹

Discover the 150 mg/mL SKYRIZI PEN^1-3

What stays the same with the SKYRIZI Pen^1,2

Same SKYRIZI you
know and trust,
in a single
150 mg/mL injection*

Consistent efficacy
and safety profile

In-office or at-home
administration after
proper training^†

*Bioequivalence was demonstrated between a single 150 mg/mL injection and two 75 mg/0.83 mL injections in a prefilled syringe.
Bioequivalence was also demonstrated between 150 mg/mL prefilled syringe and prefilled pen.

^†SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after
training in subcutaneous injection technique.¹

THE RESULTS ARE IN

In a questionnaire from a single-arm, open-label study, patients reported a
positive injection experience^3,4

AT WEEK 28

98% (n=81/83) OF PATIENTS REPORTED

EASE OF USE

SKYRIZI Pen was
easy/very easy to use

CONVENIENCE

SKYRIZI Pen was
convenient/very convenient

SATISFACTION

They were satisfied/very
satisfied self-injecting
with the SKYRIZI Pen

DESCRIPTION: In an open-label, single-arm, multicenter study evaluating the SKYRIZI Pen (N=108), patient experience was reported through questions within 6 domains of a validated Self-Injection Assessment Questionnaire (SIAQ). Graphic includes percent of patients reporting easy/very easy, convenient/very convenient, satisfied/very satisfied for 3 questions within the ease of use and satisfaction domains at Week 28 (N=83).^3,4

ADMINISTRATION INSTRUCTIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the

Instructions for Use

.¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Indications

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Important Safety Information

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210594

REFERENCES

SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
Lon H-K, Cheng L, Nudurupati S, et al. Pharmacokinetic comparability of risankizumab formulations in prefilled syringe and auto-injector for subcutaneous injection. Clin Ther. 2021;43(3):629-636. doi:10.1016/j.clinthera.2021.01.009
Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. Published online May 5, 2021. doi:10.1080/09546634.2021.1914812
Data on file, AbbVie Inc. ABVRRTI71818.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Hypersensitivity Reactions, Infections, Tuberculosis (TB), Administration of Vaccines

Hypersensitivity Reactions

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Hypersensitivity Reactions, Infections, Tuberculosis (TB), Administration of Vaccines

Hypersensitivity Reactions

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions,

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Hypersensitivity Reactions, Infections, Tuberculosis (TB), Administration of Vaccines

Hypersensitivity Reactions

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Hypersensitivity Reactions, Infections, Tuberculosis (TB), Administration of Vaccines

Hypersensitivity Reactions

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions,

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Indications

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Important Safety Information

Hypersensitivity Reactions

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

Tuberculosis (TB)

Administration of Vaccines

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210594

SKYRIZI is the only 4-dose-a-year biologic for Ps and for PsA that offers a single-dose pen1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

Indications

Important Safety Information

STUDY DESIGN – IMMvent9

SELECTED BASELINE CHARACTERISTICS9,14

STUDY DESIGN—IMMhance1,10

SELECTED BASELINE CHARACTERISTICS10

STUDY DESIGN — UltIMMa-1 and UltIMMa-21,2

SELECTED BASELINE CHARACTERISTICS1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

Indications

Important Safety Information

SKYRIZI is the only 4-dose-a-year biologic for Ps and for PsA
that offers a single-dose pen¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

STUDY DESIGN – IMMvent⁹

SELECTED BASELINE CHARACTERISTICS^9,14

STUDY DESIGN—IMMhance^1,10

SELECTED BASELINE CHARACTERISTICS¹⁰

STUDY DESIGN — UltIMMa-1 and UltIMMa-2^1,2

SELECTED BASELINE CHARACTERISTICS¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹